Search

Your search keyword '"Curio, Jonathan"' showing total 124 results
Start Over Author "Curio, Jonathan"
124 results on '"Curio, Jonathan"'

10. TCT-519 Coronary Access and Percutaneous Coronary Intervention Feasibility After Transcatheter Aortic Valve Replacement in Failed Bioprosthetic Valves With ACURATE neo2 Versus Evolut PRO+

Author

Giannini, Francesco, primary, Khokhar, Arif, additional, Curio, Jonathan, additional, Beneduce, Alessandro, additional, Fabris, Enrico, additional, Montonati, Carolina, additional, Zlahoda-Huzior, Adriana, additional, Kim, Won-Keun, additional, and Dudek, Dariusz, additional

Published
2023
Full Text
View/download PDF

14. Prophylactic Intra-Aortic Balloon Pump in Transfemoral Transcatheter Aortic Valve Replacement

Author

Scotti, Andrea, primary, Leone, Pier Pasquale, additional, Sturla, Matteo, additional, Curio, Jonathan, additional, Spring, Alexander M., additional, Ressa, Gaia, additional, Ludwig, Sebastian, additional, Sugiura, Tadahisa, additional, Assafin, Manaf, additional, Granada, Juan F., additional, Chau, Mei, additional, Doolittle, James, additional, and Latib, Azeem, additional

Published
2023
Full Text
View/download PDF

15. Comparison of BASILICA and Balloon-Assisted BASILICA Coronary Protection for Redo-TAVR:Insights From Bench Testing

Author

Beneduce, Alessandro, Khokhar, Arif A., Curio, Jonathan, Giannini, Francesco, Zlahoda-Huzior, Adriana, Grant, Daire, Maisano, Francesco, de Backer, Ole, Sathananthan, Janarthanan, Dudek, Dariusz, Beneduce, Alessandro, Khokhar, Arif A., Curio, Jonathan, Giannini, Francesco, Zlahoda-Huzior, Adriana, Grant, Daire, Maisano, Francesco, de Backer, Ole, Sathananthan, Janarthanan, and Dudek, Dariusz

Published
2023

16. Prophylactic intra-aortic balloon pump in transfemoral transcatheter aortic valve implantation

Author

Scotti, Andrea, primary, Leone, Pier Pasquale, additional, Sturla, Matteo, additional, Curio, Jonathan, additional, Spring, Alexander M., additional, Ressa, Gaia, additional, Ludwig, Sebastian, additional, Sugiura, Tadahisa, additional, Assafin, Manaf, additional, Granada, Juan F., additional, Chau, Mei, additional, Doolittle, James, additional, and Latib, Azeem, additional

Published
2023
Full Text
View/download PDF

19. Management of Volume Overload in Severe Atrial-Functional Tricuspid Regurgitation: Improved Feasibility of Transcatheter Edge-to-Edge Repair

Author

Scotti, Andrea, Curio, Jonathan, Leone, Pier Pasquale, Ludwig, Sebastian, Coisne, Augustin, Sturla, Matteo, Murthy, Sandhya, Chau, Mei, Granada, Juan F., Jorde, Ulrich P., Ho, Edwin C., and Latib, Azeem

Subjects
Case Report
Abstract

Patients with tricuspid regurgitation are often referred late in their disease course and present with volume overload, which is a detrimental factor leading to right-sided chamber dilatation and dysfunction. Treatment of volume overload can 1) improve patient functional status; 2) avoid repeated invasive examinations; and 3) establish eligibility for transcatheter tricuspid intervention. (Level of Difficulty: Intermediate.)

Published
2023

20. Identifikation klinischer Faktoren zur optimierten Patientenselektion bei interventioneller Therapie der Mitralklappeninsuffizienz mittels MitraClip Device

Author

Curio, Jonathan

Subjects
transcatheter edge-to-edge repair, MitraClip, transcatheter mitral valve repair, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
Abstract

Der MitraClip (Abbott-Laboratories) ist eine katheterbasierte Therapieoption bei schwerer Mitralklappeninsuffizienz (MI) und hohem OP-Risiko. Die progrediente Klinik der MI erschwert jedoch die Identifikation des optimalen Interventionszeitpunktes. Publikation 1 untersuchte daher, ob symptomatische Patienten mit in Ruhe moderater, unter Handgrip-Stressechokardiographie jedoch schwerer MI (MI2+) gegenüber Patienten mit bereits in Ruhe schwerer MI (MI3) bessere MitraClip-Ergebnisse zeigten. Ein weiteres wichtiges klinisches Szenario sind koinzidente moderate Aortenklappenerkrankungen. Publikation 2 untersuchte deren Beeinflussung des MitraClip-Outcomes. Trotz erfolgreichem MitraClip erleiden einige Patienten ein MI-Rezidiv, weshalb Publikation 3 Machbarkeit und Ergebnisse eines Re-MitraClip (ReClip) untersuchte. Material und Methodik Publikation 1 verglich retrospektiv 55 MI2+ Patienten mit 166 MI3 Patienten bezüglich eines kombinierten Endpunktes (Mortalität, Herzinsuffizienz-Hospitalisationen) 2 Jahre nach MitraClip, Publikation 2 verglich 21 Patienten mit koinzidenter moderater Aortenklappenstenose (AS), 28 Patienten mit moderater Aortenklappeninsuffizienz (AI) und 237 Patienten ohne relevante Aortenklappenerkrankung 1 Jahr nach MitraClip und Publikation 3 untersuchte das Outcome 1 Jahr nach 15 ReClip-Prozeduren. Ergebnisse MI3 Patienten zeigten gegenüber MI2+ Patienten signifikant höhere STS-Scores, mehr präprozedurale Herzinsuffizienz-Hospitalisationen, schlechtere linksventrikuläre (LV) Ejektionsfraktionen und verstärkte LV-Dilatation (Publikation 1). MI3 Patienten erlitten nach 2 Jahren signifikant häufiger den kombinierten Endpunkt (p=0,010). Herzinsuffizienz-Hospitalisationen waren jedoch in beiden Gruppen gegenüber den 2 präprozeduralen Jahren reduziert (MI3: p2 (14,3% vs. 8,9%, p=0,001). 11 der 15 ReClips (73%) waren erfolgreich (MI-Reduktion≥1, Mitralklappengradient, MitraClip (Abbott-Laboratories) is a catheter-based treatment for high surgical-risk patients with severe mitral regurgitation (MR). During MR progression, identification of an ideal treatment-point is challenging. Thus, publication 1 studied whether patients with moderate resting MR, progressing to severe under handgrip-exercise (MR2+) showed better outcomes than patients with severe resting MR (MR3). As concomitant aortic-valve-diseases (AVD) are another field of concern, publication 2 studied how these influence MitraClip outcomes. Despite successful MitraClip some patients experience MR recurrence. Publication 3 evaluated feasibility and outcomes of Re-MitraClip (ReClip) in such patients. Material and methods Publication 1 retrospectively compared 55 MR2+ with 166 MR3 patients, assessing a combined endpoint (mortality, heart-failure[HF]-hospitalisations) 2 years after MitraClip. Publication 2 compared 21 patients with concomitant moderate aortic-stenosis (AS), 28 patients with concomitant moderate aortic-regurgitation (AR) and 237 patients without AVD 1 year following MitraClip. Publication 3 studied outcomes in 15 patients 1 year after ReClip. Results MR3 patients compared with MR2+ showed significantly higher STS-Scores, more pre-procedural HF-hospitalisations, worse leftventricular (LV) ejection fraction und more LV-dilatation (publication 1). MR3 patients after 2 years significantly more often experienced the combined endpoint (p=0,010). HF-hospitalisations, compared to 2 years pre-procedure, were reduced in both groups (MR3: p2 (14,3% vs. 8,9%, p=0,001). 11 of 15 ReClips (73%) were successful (MR-reduction≥1, gradient

Published
2023
Full Text
View/download PDF

21. CRT-700.48 Prophylactic Intra-Aortic Balloon Pump in Transfemoral Transcatheter Aortic Valve Replacement

Author

Scotti, Andrea, primary, Leone, Pier Pasquale, additional, Sturla, Matteo, additional, Curio, Jonathan, additional, Spring, Alexander M., additional, Ressa, Gaia, additional, Ludwig, Sebastian, additional, Sugiura, Tadahisa, additional, Assafin, Manaf, additional, Granada, Juan F., additional, Chau, Mei, additional, Doolittle, James, additional, and Latib, Azeem, additional

Published
2023
Full Text
View/download PDF

29. Cerebral embolisation during transcatheter edge-to-edge repair of the mitral valve with the MitraClip system: a prospective, observational study

Author

Braemswig, Tim Braemswig, primary, Kusserow, Madeleine Kusserow, additional, Kruppa, Jochen, additional, Reinthaler, Markus, additional, Erdur, Hebun, additional, Fritsch, Merve, additional, Curio, Jonathan, additional, Alushi, Brunilda, additional, Villringer, Kersten, additional, Galinovic, Ivana, additional, Berger, Christian, additional, Leistner, David Leistner, additional, Audebert, Heinrich Audebert, additional, Endres, Matthias, additional, Landmesser, Ulf, additional, Fiebach, Jochen Fiebach, additional, Nolte, Christian Nolte, additional, Beckhoff, Frederik, additional, and Lauten, Alexander, additional

Published
2022
Full Text
View/download PDF

30. Update on supra-annular sizing of transcatheter aortic valve prostheses in raphe-type bicuspid aortic valve disease according to the LIRA method

Author

Iannopollo, Gianmarco, primary, Romano, Vittorio, additional, Esposito, Antonio, additional, Guazzoni, Giulia, additional, Ancona, Marco, additional, Ferri, Luca, additional, Russo, Filippo, additional, Bellini, Barbara, additional, Buzzatti, Nicola, additional, Curio, Jonathan, additional, Prendergast, Bernard, additional, and Montorfano, Matteo, additional

Published
2022
Full Text
View/download PDF

33. Transcatheter mitral valve replacement:Current evidence and concepts

Author

Demir, Ozan M., Bolland, Mhairi, Curio, Jonathan, Søndergaard, Lars, Rodés-Cabau, Josep, Redwood, Simon, Prendergast, Bernard, Colombo, Antonio, Chau, Mei, Latib, Azeem, Demir, Ozan M., Bolland, Mhairi, Curio, Jonathan, Søndergaard, Lars, Rodés-Cabau, Josep, Redwood, Simon, Prendergast, Bernard, Colombo, Antonio, Chau, Mei, and Latib, Azeem

Abstract

Over the past decade, several transcatheter devices have been developed to address the treatment of severe mitral regurgitation (MR) in patients at high surgical risk, mainly aimed at repairing the native mitral valve (MV). MV repair devices have recently been shown to have high efficacy and safety. However, to replicate promising trial results, specific anatomical and pathophysiological criteria have to be met and operators need a high level of experience. As yet, the longer-term durability of transcatheter MV repair remains unknown. Transcatheter MV replacement (TMVR) might be a treatment option able to target various anatomies, reliably abolish MR, and foster ease of use with a standardised implantation protocol. This review presents upcoming TMVR devices and available data and discusses how TMVR might further advance the field of transcatheter treatment of MR.

Published
2021

44. The predictive value of a modified Carpentier classification in patients with coincidental mitral regurgitation undergoing TAVI for severe aortic valve stenosis1

Author

Al-Hindwan, Haitham Saleh Ali, primary, Landmesser, Ulf, additional, Stähli, Barbara, additional, Alushi, Brunhilda, additional, Curio, Jonathan, additional, Neumann, Tim, additional, Jung, Friedrich, additional, Lendlein, Andreas, additional, Jacobs, Stephan, additional, and Reinthaler, Markus, additional

Published
2018
Full Text
View/download PDF

46. The predictive value of a modified Carpentier classification in patients with coincidental mitral regurgitation undergoing TAVI for severe aortic valve stenosis1.

Author

Al-Hindwan, Haitham Saleh Ali, Landmesser, Ulf, Stähli, Barbara, Alushi, Brunhilda, Curio, Jonathan, Neumann, Tim, Jung, Friedrich, Lendlein, Andreas, Jacobs, Stephan, and Reinthaler, Markus

Subjects
MITRAL valve insufficiency, AORTIC stenosis, ETIOLOGY of heart valve diseases, HEART dilatation, AORTIC valve surgery, PATIENTS
Abstract

INTRODUCTION: Concomitant mitral-regurgitation (MR) is frequently observed in patients undergoing trans-catheter aortic valve implantation (TAVI). The predictive value of MR etiology remains to be elucidated. METHODS: 600 patients with coincidental MR (≥moderate) undergoing TAVI were categorized according to a modified Carpentier classification [Groups: no/mild MR, n = 477; left atrial (LA) functional MR, n = 18; MR due to left ventricular dilatation, n = 29; degenerative MR, n = 50; MR with restricted leaflet motion n = 26]. MR improvement and patient outcome was compared among the groups in a retrospective analysis. RESULTS: MR regression was most pronounced in patients with restricted leaflet motion after 6 months, although a significant improvement was observed in all subgroups. MR relief was predominantly observed within the first 30 days after TAVI. Only patients with restricted leaflet motion experienced further improvement thereafter. In the entire cohort a total of 15 strokes (2.5%) during the first 30 days after TAVI were observed, with the highest incidence in the LA functional cohort (3 events, 17%; p = 0.008). In multivariate analysis, organic etiology was associated with an increased 1-year mortality. In conclusion, despite significant MR regression in all MR groups, some individuals may require additional mitralvalve repair after TAVI. According to our data the timing of these procedures should be based on the underlying MR etiology. The Carpentier classification in patients with coincidental MR undergoing TAVI for severe AS may also have prognostic implications as we found an increased incidence of strokes in our LA functional cohort and a worse mortality rates in organic MR. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

48. The predictive value of a modified Carpentier classification in patients with coincidental mitral regurgitation undergoing TAVI for severe aortic valve stenosis1.

Author

Al-Hindwan, Haitham Saleh Ali, Landmesser, Ulf, Stähli, Barbara, Alushi, Brunhilda, Curio, Jonathan, Neumann, Tim, Jung, Friedrich, Lendlein, Andreas, Jacobs, Stephan, and Reinthaler, Markus

Subjects
*MITRAL valve insufficiency, *AORTIC stenosis, *ETIOLOGY of heart valve diseases, *HEART dilatation, *PATIENTS, AORTIC valve surgery
Abstract

INTRODUCTION: Concomitant mitral-regurgitation (MR) is frequently observed in patients undergoing trans-catheter aortic valve implantation (TAVI). The predictive value of MR etiology remains to be elucidated. METHODS: 600 patients with coincidental MR (≥moderate) undergoing TAVI were categorized according to a modified Carpentier classification [Groups: no/mild MR, n = 477; left atrial (LA) functional MR, n = 18; MR due to left ventricular dilatation, n = 29; degenerative MR, n = 50; MR with restricted leaflet motion n = 26]. MR improvement and patient outcome was compared among the groups in a retrospective analysis. RESULTS: MR regression was most pronounced in patients with restricted leaflet motion after 6 months, although a significant improvement was observed in all subgroups. MR relief was predominantly observed within the first 30 days after TAVI. Only patients with restricted leaflet motion experienced further improvement thereafter. In the entire cohort a total of 15 strokes (2.5%) during the first 30 days after TAVI were observed, with the highest incidence in the LA functional cohort (3 events, 17%; p = 0.008). In multivariate analysis, organic etiology was associated with an increased 1-year mortality. In conclusion, despite significant MR regression in all MR groups, some individuals may require additional mitralvalve repair after TAVI. According to our data the timing of these procedures should be based on the underlying MR etiology. The Carpentier classification in patients with coincidental MR undergoing TAVI for severe AS may also have prognostic implications as we found an increased incidence of strokes in our LA functional cohort and a worse mortality rates in organic MR. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

49. Evaluating Lifetime Coronary Access After TAVR: Insights From Bench Testing in Patient-Specific Anatomies.

Author

Khokhar AA, Beneduce A, Guerreiro C, Curio J, Huzior AZ, Giannini F, De Backer O, Teles R, and Dudek D

Abstract

Competing Interests: Funding Support and Author Disclosures Drs Khokhar, Beneduce, Giannini, De Backer, and Teles have all received speaker fees from Boston Scientific. Dr Dudek has received an ISR grant from Boston Scientific. This study was partially funded by Boston Scientific who only provided the materials required for bench-testing and simulation. Boston Scientific were not involved in the design of the study, methodology or manuscript. Boston Scientific was not involved in the design of the study, methodology, or manuscript preparation. Drs Khokhar, Beneduce, Giannini, De Backer, and Teles have received speaker fees from Boston Scientific. Dr Dudek has received an investigator-sponsored research grant from Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results